Beyond high-dose methotrexate and brain radiotherapy

Novel targets and agents for primary CNS lymphoma

M. Ponzoni, S. Issa, T. T. Batchelor, J. L. Rubenstein

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. Patients and methods: We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. Results: While PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. Conclusions: There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive sideeffects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.

Original languageEnglish
Article numbermdt385
Pages (from-to)316-322
Number of pages7
JournalAnnals of Oncology
Volume25
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Central Nervous System Agents
Methotrexate
Lymphoma
Radiotherapy
Central Nervous System
Brain
Radiation
Drug Therapy
Germinal Center
Tumor Microenvironment
Lymphoma, Large B-Cell, Diffuse
Chemokines
B-Lymphocytes
Phosphotransferases
Survival Rate
Macrophages
Research Personnel
T-Lymphocytes
Survival
Therapeutics

Keywords

  • B-cell receptor
  • Novel agents
  • Primary CNS lymphoma
  • Protein kinases
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Beyond high-dose methotrexate and brain radiotherapy : Novel targets and agents for primary CNS lymphoma. / Ponzoni, M.; Issa, S.; Batchelor, T. T.; Rubenstein, J. L.

In: Annals of Oncology, Vol. 25, No. 2, mdt385, 02.2014, p. 316-322.

Research output: Contribution to journalArticle

Ponzoni, M. ; Issa, S. ; Batchelor, T. T. ; Rubenstein, J. L. / Beyond high-dose methotrexate and brain radiotherapy : Novel targets and agents for primary CNS lymphoma. In: Annals of Oncology. 2014 ; Vol. 25, No. 2. pp. 316-322.
@article{1ce1b4f53b484b02ad0282401b4f1378,
title = "Beyond high-dose methotrexate and brain radiotherapy: Novel targets and agents for primary CNS lymphoma",
abstract = "Background: While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. Patients and methods: We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. Results: While PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. Conclusions: There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive sideeffects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.",
keywords = "B-cell receptor, Novel agents, Primary CNS lymphoma, Protein kinases, Tumor microenvironment",
author = "M. Ponzoni and S. Issa and Batchelor, {T. T.} and Rubenstein, {J. L.}",
year = "2014",
month = "2",
doi = "10.1093/annonc/mdt385",
language = "English",
volume = "25",
pages = "316--322",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Beyond high-dose methotrexate and brain radiotherapy

T2 - Novel targets and agents for primary CNS lymphoma

AU - Ponzoni, M.

AU - Issa, S.

AU - Batchelor, T. T.

AU - Rubenstein, J. L.

PY - 2014/2

Y1 - 2014/2

N2 - Background: While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. Patients and methods: We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. Results: While PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. Conclusions: There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive sideeffects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.

AB - Background: While there has been significant progress in outcomes for patients diagnosed with primary central nervous system (CNS) lymphoma (PCNSL), survival rates will likely plateau with the current armamentarium of agents used to treat these patients. Moreover, given that PCNSL increasingly impacts an older population, a significant proportion of patients are not eligible for intensive therapies such as high-dose chemotherapy or whole-brain radiation. There is a need for the development of novel agents, which target key survival pathways in order to continue to make progress in this disease. Patients and methods: We reviewed the key molecular pathways and genomic aberrations in PCNSL in order to identify candidate targets. We focused on molecules and pathways that have been identified and confirmed by more than one investigator or methodology. Results: While PCNSL tumors usually express a BCL6+, MUM1+ 'activated, germinal center' immunophenotype, they exhibit multiple shared genetic properties with ABC-type diffuse large B-cell lymphomas. Candidate targets and pathways include NFkB, the B-cell receptor, the JAK/STAT pathway, IRF4, BCL-6 as well as PIM kinases. Elements of the tumor microenvironment that may be exploited therapeutically include chemokine pathways, as well as macrophage and T-cell responses. Conclusions: There is a significant need for developing novel therapies in PCNSL, given that an increasing proportion of patients are not eligible for high-dose chemotherapy and brain radiation is associated with detrimental cognitive sideeffects. We provide an overview of potential drug targets and novel agents that may be integrated with existing strategies in order to make further progress in this disease.

KW - B-cell receptor

KW - Novel agents

KW - Primary CNS lymphoma

KW - Protein kinases

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84893341826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893341826&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt385

DO - 10.1093/annonc/mdt385

M3 - Article

VL - 25

SP - 316

EP - 322

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

M1 - mdt385

ER -